title: Pharmacological characterization of the specific binding of [3H]ryanodine to rat brain microsomal membranes.
abstract: High-affinity binding of [3H]ryanodine has been characterized in rat brain microsomal fractions. Membrane fractions from 4 brain regions (cerebral cortex, cerebellum, hippocampus and brainstem) have been isolated using sucrose density gradient purification. Sodium dodecyl sulfate polyacrylamide gel electrophoresis showed the presence of a high-molecular weight protein (Mr approximately 320 kDa), similar to that of ryanodine receptor from muscle sarcoplasmic reticulum (SR). In the presence of high salt (1 M KCl), [3H]ryanodine binds to low density (0.8 M sucrose) cortical microsomal fraction with high affinity (Kd 1.5 nM), and with the highest capacity (Bmax 330 fmol/mg protein). Kinetic analysis of the binding suggests multiple available binding sites for ryanodine. Binding of ryanodine is Ca2+ dependent (ED50 1 microM) and inhibited by Mg2+ and Ruthenium red. Adenine nucleotides have a biphasic effect on the binding of [3H]ryanodine. At low Ca2+ concentration caffeine and daunorubicin enhance the binding of [3H]ryanodine. The inositol 1,4,5-trisphosphate (IP3) binding inhibitor, heparin, has no effect on ryanodine binding, and ryanodine and caffeine do not influence the binding of [3H]IP3, which is enriched in the cerebellar fractions. These data demonstrate significant quantitative differences in the pharmacology of brain and muscle receptors and raise the question as to the physiological role of ryanodine binding proteins in the central nervous system and whether it is coupled to an endoplasmatic reticulum (ER) Ca2+ release channel.
authors.affiliation: Department of Veterinary Pharmacology and Toxicology, University of California, Davis 95616.
authors.forename: I
authors.initials: I
authors.lastname: Zimanyi
authors.forename: I N
authors.initials: IN
authors.lastname: Pessah
mesh_terms: D000251:Adenosine Triphosphatases / Q000378:metabolism; D000818:Animals; D001921:Brain / Q000378:metabolism*; D002118:Calcium / Q000494:pharmacology; D015220:Calcium Channels; D002458:Cell Fractionation; D002499:Centrifugation, Density Gradient; D004591:Electrophoresis, Polyacrylamide Gel; D015544:Inositol 1,4,5-Trisphosphate / Q000378:metabolism; D053496:Inositol 1,4,5-Trisphosphate Receptors; D007425:Intracellular Membranes / Q000378:metabolism*; D007700:Kinetics; D008274:Magnesium / Q000494:pharmacology; D008861:Microsomes / Q000378:metabolism*; D008970:Molecular Weight; D009928:Organ Specificity; D051381:Rats; D011919:Rats, Inbred Strains; D011956:Receptors, Cell Surface / Q000378:metabolism; D011950:Receptors, Cholinergic / Q000187:drug effects / Q000302:isolation & purification / Q000378:metabolism*; D018160:Receptors, Cytoplasmic and Nuclear; D012433:Ryanodine / Q000378:metabolism*; D019837:Ryanodine Receptor Calcium Release Channel
chemical_list: D015220:Calcium Channels; D053496:Inositol 1,4,5-Trisphosphate Receptors; D011956:Receptors, Cell Surface; D011950:Receptors, Cholinergic; D018160:Receptors, Cytoplasmic and Nuclear; D019837:Ryanodine Receptor Calcium Release Channel; D012433:Ryanodine; D015544:Inositol 1,4,5-Trisphosphate; D000251:Adenosine Triphosphatases; D008274:Magnesium; D002118:Calcium